vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与弗雷斯特研究公司（FORR）财务数据对比。点击上方公司名可切换其他公司
CATALYST PHARMACEUTICALS, INC.的季度营收约是弗雷斯特研究公司的1.5倍（$152.6M vs $101.1M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs -33.5%，领先68.1%），CATALYST PHARMACEUTICALS, INC.同比增速更快（7.6% vs -6.5%），CATALYST PHARMACEUTICALS, INC.自由现金流更多（$44.9M vs $-4.3M），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs 0.5%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
福雷斯特研究公司是一家全球领先的研究咨询机构，主营业务涵盖行业研究、管理咨询与行业峰会举办，客户群体包括全球大型企业、科技公司与消费领域领军企业，公司总部位于美国马萨诸塞州剑桥市。
CPRX vs FORR — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $101.1M |
| 净利润 | $52.7M | $-33.9M |
| 毛利率 | 82.9% | 56.7% |
| 营业利润率 | 40.5% | -36.6% |
| 净利率 | 34.5% | -33.5% |
| 营收同比 | 7.6% | -6.5% |
| 净利润同比 | -5.8% | -7941.4% |
| 每股收益（稀释后） | $0.40 | $-1.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $152.6M | $101.1M | ||
| Q3 25 | $148.4M | $94.3M | ||
| Q2 25 | $146.6M | $111.7M | ||
| Q1 25 | $141.4M | $89.9M | ||
| Q4 24 | $141.8M | $108.0M | ||
| Q3 24 | $128.7M | $102.5M | ||
| Q2 24 | $122.7M | $121.8M | ||
| Q1 24 | $98.5M | $100.1M |
| Q4 25 | $52.7M | $-33.9M | ||
| Q3 25 | $52.8M | $-2.1M | ||
| Q2 25 | $52.1M | $3.9M | ||
| Q1 25 | $56.7M | $-87.3M | ||
| Q4 24 | $55.9M | $432.0K | ||
| Q3 24 | $43.9M | $-5.8M | ||
| Q2 24 | $40.8M | $6.3M | ||
| Q1 24 | $23.3M | $-6.7M |
| Q4 25 | 82.9% | 56.7% | ||
| Q3 25 | 84.7% | 60.0% | ||
| Q2 25 | 85.9% | 55.5% | ||
| Q1 25 | 87.3% | 55.9% | ||
| Q4 24 | 84.7% | 58.8% | ||
| Q3 24 | 85.0% | 60.5% | ||
| Q2 24 | 87.4% | 57.3% | ||
| Q1 24 | 87.3% | 54.9% |
| Q4 25 | 40.5% | -36.6% | ||
| Q3 25 | 44.7% | 4.7% | ||
| Q2 25 | 45.2% | 6.2% | ||
| Q1 25 | 44.8% | -97.5% | ||
| Q4 24 | 44.3% | -0.5% | ||
| Q3 24 | 39.6% | -0.7% | ||
| Q2 24 | 44.2% | 9.3% | ||
| Q1 24 | 27.5% | -9.3% |
| Q4 25 | 34.5% | -33.5% | ||
| Q3 25 | 35.6% | -2.3% | ||
| Q2 25 | 35.6% | 3.5% | ||
| Q1 25 | 40.1% | -97.1% | ||
| Q4 24 | 39.4% | 0.4% | ||
| Q3 24 | 34.1% | -5.7% | ||
| Q2 24 | 33.2% | 5.2% | ||
| Q1 24 | 23.6% | -6.7% |
| Q4 25 | $0.40 | $-1.75 | ||
| Q3 25 | $0.42 | $-0.11 | ||
| Q2 25 | $0.41 | $0.20 | ||
| Q1 25 | $0.45 | $-4.62 | ||
| Q4 24 | $0.44 | $0.02 | ||
| Q3 24 | $0.35 | $-0.30 | ||
| Q2 24 | $0.33 | $0.33 | ||
| Q1 24 | $0.19 | $-0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $63.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $954.3M | $126.5M |
| 总资产 | $1.1B | $404.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $709.2M | $63.3M | ||
| Q3 25 | $689.9M | $65.1M | ||
| Q2 25 | $652.8M | $67.8M | ||
| Q1 25 | $580.7M | $75.6M | ||
| Q4 24 | $517.6M | $56.1M | ||
| Q3 24 | $442.3M | $62.8M | ||
| Q2 24 | $375.7M | $58.9M | ||
| Q1 24 | $310.4M | $61.4M |
| Q4 25 | $954.3M | $126.5M | ||
| Q3 25 | $920.2M | $157.7M | ||
| Q2 25 | $856.0M | $159.5M | ||
| Q1 25 | $794.3M | $147.4M | ||
| Q4 24 | $727.6M | $229.5M | ||
| Q3 24 | $660.9M | $234.3M | ||
| Q2 24 | $608.7M | $237.1M | ||
| Q1 24 | $561.4M | $230.9M |
| Q4 25 | $1.1B | $404.0M | ||
| Q3 25 | $1.1B | $414.2M | ||
| Q2 25 | $971.9M | $436.0M | ||
| Q1 25 | $908.9M | $439.8M | ||
| Q4 24 | $851.4M | $503.9M | ||
| Q3 24 | $772.0M | $505.3M | ||
| Q2 24 | $706.4M | $524.2M | ||
| Q1 24 | $646.7M | $555.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $-3.2M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | $-4.3M |
| 自由现金流率自由现金流/营收 | 29.4% | -4.2% |
| 资本支出强度资本支出/营收 | 0.0% | 1.1% |
| 现金转化率经营现金流/净利润 | 0.85× | — |
| 过去12个月自由现金流最近4个季度 | — | $18.1M |
8季度趋势，按日历期对齐
| Q4 25 | $44.9M | $-3.2M | ||
| Q3 25 | $32.4M | $1.2M | ||
| Q2 25 | $71.3M | $-3.6M | ||
| Q1 25 | $60.0M | $26.7M | ||
| Q4 24 | $70.9M | $-1.8M | ||
| Q3 24 | $72.9M | $264.0K | ||
| Q2 24 | $64.1M | $-2.9M | ||
| Q1 24 | $31.9M | $611.0K |
| Q4 25 | $44.9M | $-4.3M | ||
| Q3 25 | — | $524.0K | ||
| Q2 25 | $71.3M | $-4.2M | ||
| Q1 25 | — | $26.1M | ||
| Q4 24 | $70.8M | $-2.5M | ||
| Q3 24 | $72.6M | $-223.0K | ||
| Q2 24 | $64.1M | $-3.7M | ||
| Q1 24 | $31.7M | $-815.0K |
| Q4 25 | 29.4% | -4.2% | ||
| Q3 25 | — | 0.6% | ||
| Q2 25 | 48.6% | -3.8% | ||
| Q1 25 | — | 29.0% | ||
| Q4 24 | 49.9% | -2.3% | ||
| Q3 24 | 56.4% | -0.2% | ||
| Q2 24 | 52.3% | -3.1% | ||
| Q1 24 | 32.2% | -0.8% |
| Q4 25 | 0.0% | 1.1% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.0% | 0.5% | ||
| Q1 25 | 0.0% | 0.7% | ||
| Q4 24 | 0.1% | 0.6% | ||
| Q3 24 | 0.2% | 0.5% | ||
| Q2 24 | 0.0% | 0.7% | ||
| Q1 24 | 0.2% | 1.4% |
| Q4 25 | 0.85× | — | ||
| Q3 25 | 0.61× | — | ||
| Q2 25 | 1.37× | -0.93× | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 1.27× | -4.24× | ||
| Q3 24 | 1.66× | — | ||
| Q2 24 | 1.57× | -0.46× | ||
| Q1 24 | 1.37× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
FORR
| Research Segment | $82.2M | 81% |
| Consulting Segment | $16.2M | 16% |
| Billable Expenses | $1.5M | 2% |
| Professional Services | $1.4M | 1% |
